Biomarkers for Risk Stratification in Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 40 lat
- •Zdolność do zrozumienia i podpisania pisemnej zgody
- •Chęć uczestnictwa w badaniu i oddawania próbek krwi
- •Chęć uczestnictwa w obserwacji przez 3 lata
✗ Disqualifies
- •Inny nowotwór (poza rakiem skóry) w ciągu ostatnich 5 lat
- •Niedokrwistość - niski poziom hemoglobiny
- •Niedożywienie - zbyt niski wskaźnik masy ciała
- •Ciężka choroba płuc (zaawansowana PZWL)
- •Niestabilne problemy z sercem lub niedawny zawał
- •Marskość wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 40 Years
- Last updated (source)
- October 14, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, United States
San Francisco VA Medical Center
San Francisco, United States
University of California, San Francisco
San Francisco, United States
Trial contact
Mehrdad Arjomandi, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.